Diseases /
High Grade Ovarian Serous Adenocarcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A rapidly growing serous adenocarcinoma that arises from the ovary. It is characterized by the presence of high grade cytologic features and frequent mitotic figures. [1]
High grade ovarian serous adenocarcinomas most frequently harbor alterations in TP53, CCNE1, BRCA1, NF1, and MYC [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, TP53 Exon 5 Mutation, and TP53 Exon 7 Mutation are the most common alterations in high grade ovarian serous adenocarcinoma [2].
There are 52 clinical trials for high grade ovarian serous adenocarcinoma, of which 46 are open and 6 are completed or closed. Of the trials that contain high grade ovarian serous adenocarcinoma as an inclusion criterion, 22 are phase 1 (21 open), 9 are phase 1/phase 2 (7 open), 15 are phase 2 (12 open), and 6 are phase 3 (6 open).
BRCA1, BRCA2, and ATM are the most frequent gene inclusion criteria for high grade ovarian serous adenocarcinoma clinical trials [3].
Carboplatin, paclitaxel, and olaparib are the most common interventions in high grade ovarian serous adenocarcinoma clinical trials.
Significant Genes in High Grade Ovarian Serous Adenocarcinoma
ALK +
ALK is altered in 2.85% of high grade ovarian serous adenocarcinoma patients [2].
ALK is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
ARID1A +
ARID1A is altered in 4.46% of high grade ovarian serous adenocarcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
ATM +
ATM is altered in 3.61% of high grade ovarian serous adenocarcinoma patients [2].
ATM is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
ATR +
ATR is altered in 2.42% of high grade ovarian serous adenocarcinoma patients [2].
ATR is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
ATRX +
ATRX is altered in 4.35% of high grade ovarian serous adenocarcinoma patients [2].
ATRX is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
BARD1 +
BARD1 is altered in 1.35% of high grade ovarian serous adenocarcinoma patients [2].
BARD1 is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BARD1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
BRCA1 +
BRCA1 is altered in 9.01% of high grade ovarian serous adenocarcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 12 clinical trials for high grade ovarian serous adenocarcinoma, of which 7 are open and 5 are closed. Of the trials that contain BRCA1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 6 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].
BRCA2 +
BRCA2 is altered in 6.76% of high grade ovarian serous adenocarcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 12 clinical trials for high grade ovarian serous adenocarcinoma, of which 7 are open and 5 are closed. Of the trials that contain BRCA2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 6 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].
BRIP1 +
BRIP1 is altered in 1.69% of high grade ovarian serous adenocarcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRIP1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
C11ORF30 +
C11orf30 is altered in 0.83% of high grade ovarian serous adenocarcinoma patients [2].
C11orf30 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains C11orf30 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
CCNE1 +
CCNE1 is altered in 10.46% of high grade ovarian serous adenocarcinoma patients [2].
CCNE1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
CDK12 +
CDK12 is altered in 4.59% of high grade ovarian serous adenocarcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK12 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
CHEK1 +
CHEK1 is altered in 0.46% of high grade ovarian serous adenocarcinoma patients [2].
CHEK1 is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
CHEK2 +
CHEK2 is altered in 1.56% of high grade ovarian serous adenocarcinoma patients [2].
CHEK2 is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
EGFR +
EGFR is altered in 1.36% of high grade ovarian serous adenocarcinoma patients [2].
EGFR is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
ERCC2 +
ERCC2 is altered in 2.11% of high grade ovarian serous adenocarcinoma patients [2].
ERCC2 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
ERCC3 +
ERCC3 is altered in 0.84% of high grade ovarian serous adenocarcinoma patients [2].
ERCC3 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC3 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
ERCC4 +
ERCC4 is altered in 0.71% of high grade ovarian serous adenocarcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC4 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
ERCC5 +
ERCC5 is altered in 1.57% of high grade ovarian serous adenocarcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC5 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
ERCC6 +
ERCC6 is altered in 0.46% of high grade ovarian serous adenocarcinoma patients [2].
ERCC6 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC6 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
FANCA +
FANCA is altered in 2.35% of high grade ovarian serous adenocarcinoma patients [2].
FANCA is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCA status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
FANCB +
FANCB is altered in 2.05% of high grade ovarian serous adenocarcinoma patients [2].
FANCB is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCB status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
FANCC +
FANCC is altered in 1.2% of high grade ovarian serous adenocarcinoma patients [2].
FANCC is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCC status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
FANCD2 +
FANCD2 is altered in 1.8% of high grade ovarian serous adenocarcinoma patients [2].
FANCD2 is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCD2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
FANCE +
FANCE is altered in 1.9% of high grade ovarian serous adenocarcinoma patients [2].
FANCE is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCE status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
FANCF +
FANCF is altered in 0.69% of high grade ovarian serous adenocarcinoma patients [2].
FANCF is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCF status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
FANCG +
FANCG is altered in 1.07% of high grade ovarian serous adenocarcinoma patients [2].
FANCG is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCG status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
FANCI +
FANCI is altered in 2.53% of high grade ovarian serous adenocarcinoma patients [2].
FANCI is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCI status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
FANCL +
FANCL is altered in 1.02% of high grade ovarian serous adenocarcinoma patients [2].
FANCL is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCL status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
FANCM +
FANCM is altered in 2.56% of high grade ovarian serous adenocarcinoma patients [2].
FANCM is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCM status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains HDAC1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains HDAC2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
KRAS +
KRAS is altered in 4.17% of high grade ovarian serous adenocarcinoma patients [2].
KRAS is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MDM2 +
MDM2 is altered in 1.74% of high grade ovarian serous adenocarcinoma patients [2].
MDM2 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MDM4 +
MDM4 is altered in 0.48% of high grade ovarian serous adenocarcinoma patients [2].
MDM4 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MET +
MET is altered in 1.61% of high grade ovarian serous adenocarcinoma patients [2].
MET is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MLF1 +
MLF1 is altered in 0.56% of high grade ovarian serous adenocarcinoma patients [2].
MLF1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLF1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MLH1 +
MLH1 is altered in 1.03% of high grade ovarian serous adenocarcinoma patients [2].
MLH1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MLH3 +
MLH3 is altered in 2.19% of high grade ovarian serous adenocarcinoma patients [2].
MLH3 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH3 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MRE11A +
MRE11A is altered in 0.96% of high grade ovarian serous adenocarcinoma patients [2].
MRE11A is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MRE11A status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
MSH2 +
MSH2 is altered in 1.81% of high grade ovarian serous adenocarcinoma patients [2].
MSH2 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MSH3 +
MSH3 is altered in 0.41% of high grade ovarian serous adenocarcinoma patients [2].
MSH3 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH3 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MSH6 +
MSH6 is altered in 1.56% of high grade ovarian serous adenocarcinoma patients [2].
MSH6 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH6 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MUTYH +
MUTYH is altered in 0.65% of high grade ovarian serous adenocarcinoma patients [2].
MUTYH is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MUTYH status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
MYC +
MYC is altered in 8.24% of high grade ovarian serous adenocarcinoma patients [2].
MYC is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
NBN +
NBN is altered in 1.6% of high grade ovarian serous adenocarcinoma patients [2].
NBN is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain NBN status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
NPM1 +
NPM1 is altered in 0.41% of high grade ovarian serous adenocarcinoma patients [2].
NPM1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
PALB2 +
PALB2 is altered in 1.29% of high grade ovarian serous adenocarcinoma patients [2].
PALB2 is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PALB2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
PARP1 +
PARP1 is altered in 1.12% of high grade ovarian serous adenocarcinoma patients [2].
PARP1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
PARP2 +
PARP2 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
PIK3CA +
PIK3CA is altered in 5.92% of high grade ovarian serous adenocarcinoma patients [2].
PIK3CA is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
PMS1 +
PMS1 is altered in 1.33% of high grade ovarian serous adenocarcinoma patients [2].
PMS1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PMS1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
PMS2 +
PMS2 is altered in 0.63% of high grade ovarian serous adenocarcinoma patients [2].
PMS2 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PMS2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
POLE +
POLE is altered in 1.52% of high grade ovarian serous adenocarcinoma patients [2].
POLE is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain POLE status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
PPP2R1A +
PPP2R1A is altered in 2.68% of high grade ovarian serous adenocarcinoma patients [2].
PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PPP2R1A status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PPP2R2A status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].
PTEN +
PTEN is altered in 2.71% of high grade ovarian serous adenocarcinoma patients [2].
PTEN is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAD50 +
RAD50 is altered in 1.09% of high grade ovarian serous adenocarcinoma patients [2].
RAD50 is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
RAD51 +
RAD51 is altered in 0.53% of high grade ovarian serous adenocarcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
RAD51B +
RAD51B is altered in 0.16% of high grade ovarian serous adenocarcinoma patients [2].
RAD51B is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
RAD51C +
RAD51C is altered in 1.05% of high grade ovarian serous adenocarcinoma patients [2].
RAD51C is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51C status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
RAD51D +
RAD51D is altered in 1.14% of high grade ovarian serous adenocarcinoma patients [2].
RAD51D is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51D status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
RAD54L +
RAD54L is altered in 0.49% of high grade ovarian serous adenocarcinoma patients [2].
RAD54L is an inclusion eligibility criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
RB1 +
RB1 is altered in 4.45% of high grade ovarian serous adenocarcinoma patients [2].
RB1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
RET +
RET is altered in 1.61% of high grade ovarian serous adenocarcinoma patients [2].
RET is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
ROS1 +
ROS1 is altered in 3.23% of high grade ovarian serous adenocarcinoma patients [2].
ROS1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].
SLX4 +
SLX4 is altered in 2.41% of high grade ovarian serous adenocarcinoma patients [2].
SLX4 is an inclusion eligibility criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain SLX4 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].
SMARCB1 +
SMARCB1 is altered in 1.24% of high grade ovarian serous adenocarcinoma patients [2].
SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
STAG2 +
STAG2 is altered in 2.29% of high grade ovarian serous adenocarcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
STK11 +
STK11 is altered in 1.43% of high grade ovarian serous adenocarcinoma patients [2].
STK11 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains STK11 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
TP53 +
TP53 is altered in 89.66% of high grade ovarian serous adenocarcinoma patients [2].
TP53 is an inclusion eligibility criterion in 4 clinical trials for high grade ovarian serous adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain TP53 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].
XRCC1 +
XRCC1 is altered in 3.59% of high grade ovarian serous adenocarcinoma patients [2].
XRCC1 is an inclusion eligibility criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains XRCC1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.